Apollomics Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation Posted on 2023-10-312024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion Posted on 2023-10-262024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% Posted on 2023-10-232024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 Posted on 2023-10-162024-03-13 by maxproadmin More >>